UT Health San Antonio MD Anderson Cancer Center | Strategic Alliance Partners

Latest from UT Health San Antonio MD Anderson Cancer Center

PARP Inhibitors Are Under Study as Treatment Options Beyond BRCA-Mutated Breast Cancer

May 09, 2022

Virginia G. Kaklamani, MD, discussed the emerging role of PARP inhibitors, practice-changing updates in HER2-positive breast cancer, the utilization of CDK4/6 inhibitors in hormone receptor–positive, HER2-negative breast cancer, and the various therapeutic classes and their effects on care in triple-negative breast cancer.

Momelotinib Trial Seeks to Address Myelofibrosis Symptoms

January 06, 2021

January 6, 2021 - The MOMENTUM trial will randomize patients to receive momelotinib or danazol to determine which regimen shows more efficacy against the MF hallmarks of anemia, constitutional symptoms, and splenomegaly.